research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Reform UK councillor Sean Matthews is selected to be the new leader of Lincolnshire County Council. Luke Shingler, Reform UK councillor for Nuneaton's Galley Common on Warwickshire County Council, leaves the party to sit as an independent. 12 May – Adrian Ramsay and Ellie Chowns launch a joint campaign to become co-leaders of the Green Party of England and Wales in the upcoming leadership election. 13 May – Labour MP Tahir Ali is being investigated by the Independent Parliamentary Standards Authority over excessive expenses. Conservative MP Patrick Spencer is charged with two sexual assaults that allegedly took place at London's Groucho Club. MSPs vote 70–56 in an initial vote to accept the principles of the Assisted Dying for Terminally Ill Adults (Scotland) Bill, which would allow assisted dying in Scotland. Reform UK leader Nigel Farage says he will not stand in the 2026 Senedd election and has no plans to lead the party in Wales. 14 May – The Crown Prosecution Service announces that ex-Reform MP Rupert Lowe will not face charges over alleged threats to party chairman Zia Yusuf. 15 May – Lowe, who was suspended from the Reform UK party in March, accuses Farage of running the party like a cult. 16 May – Welsh Conservatives leader Darren Millar tells his party's annual conference that the Conservatives may need to work with Plaid Cymru or Reform UK to form a government following the next Senedd election. 17 May – Darren Millar describes Reform UK as a "one-man personality cult" with no serious solution for Wales.
==== Niccolò Figà-Talamanca ==== Niccolò Figà-Talamanca, the secretary-general of the NGO No Peace Without Justice, was one of the original four suspects arrested in the case. On 14 December 2022, Figà-Talamanca was released from prison with an electronic bracelet to track his movements, but the Belgian federal prosecutor successfully appealed the order on 27 December 2022, so Figà-Talamanca went back to prison. Figà-Talamanca was released from prison without conditions by the investigative judge at a hearing on 3 February 2023. Figà-Talamanca's lawyer at the hearings was Barbara Huylebroek. According to a member of his family, Figà-Talamanca remains charged.
Connective tissue in skeletal muscle Dorsal artery of the penis (example of integument enclosing an internal organ) Flensing Flesh (generic use of plural "integuments") Herzog & de Meuron (figurative usage) Integumentary system (senses related to vertebrate skin and medical aspects) Integumental muscles Mosasaur Seed
== External links == Sugimura T, Nagao M, Wakabayashi K (May 1996). "Carcinogenicity of food mutagens". Environmental Health Perspectives. 104 (Suppl 3): 429–33. doi:10.2307/3432798. JSTOR 3432798. PMC 1469643. PMID 8781358. Louis ED, Zheng W, Jiang W, Bogen KT, Keating GA (June 2007). "Quantification of the neurotoxic beta-carboline harmane in barbecued/grilled meat samples and correlation with level of doneness". Journal of Toxicology and Environmental Health, Part A. 70 (12): 1014–9. Bibcode:2007JTEHA..70.1014L. doi:10.1080/15287390601172015. PMC 4993204. PMID 17497412.
Sources: en.wikipedia.org
== Clinical Significance == Many diseases such as Human African trypanosomiasis, Nagana disease in cattle, and Chagas disease are caused by kinetoplastid parasites. Such diseases infect an estimated 15 to 20 million people per year worldwide and kill 100000 to 150000 of those infected. Current treatments for these diseases were generally made almost 100 years ago and in that time many of the parasites have developed resistance, in addition, many of the original treatments are highly toxic. Targeting trypanothione synthase could be a novel way of preventing and curing these diseases through disruption of the parasites' metabolism. Scientists believe that the thiol metabolic pathway is an especially good target for anti-parasitic drug production as trypanothione based thiol redox is absent in humans and it is thought that thiol redox is key in the mechanisms some parasites have in order to obtain drug resistance .
== tRNA-targeting antibiotics == Oxazolidines (e.g. linezolid) prevent the binding of the initiator tRNA at the P-site. Oxazolidines have been demonstrated to pleiotropically affect initiator-tRNA binding, EF-P (elongation factor P)-stimulated synthesis of peptide bonds, and EF-G-mediated translocation of initiator-tRNA into the P-site. Macrolide, lincosamide and streptogramin classes of antibiotics prevent peptide bond formation and/or the translocation of tRNA from the A-site to the P-site on the ribosome that eventually leads to interference with the elongation step and thus the inhibition of protein translation.
The Appalachian Mountains are a vast mountain range situated in eastern North America, extending roughly 2,050 miles (3,300 km) from central Alabama to Newfoundland along a generally southwest–northeast axis. Alongside the Appalachian Plateau province—with which they are not entirely synonymous—the mountains form a wider system comprising the region's backbone. The range's highest peak is 6,684-foot (2,037 m) Mount Mitchell in the Black Mountains subrange of North Carolina, which themselves are part of the larger Blue Ridge Mountains. Saint Pierre and Miquelon, an overseas collectivity of France, is part of the range, meaning it technically spans portions of three countries. It is geologically related to the Scottish Highlands, Atlas Mountains, Scandinavian Mountains, and Ouachitas, as these ranges all originally belonged to the sprawling Central Pangean Mountains before plate tectonics tore them apart. The geologic processes that led to the formation of the Appalachian Mountains started around 1.1 billion years ago with the creation of supercontinent Rodinia, and many Precambrian rocks and minerals created via this process remain visible today in the range's outcrops. The modern Appalachians and their relatives themselves were created by a series of three distinct orogenies beginning approximately 480 million years ago, making them one of the oldest surviving mountain ranges in the world.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.